"Lymphangioleiomyomatosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).
| Descriptor ID |
D018192
|
| MeSH Number(s) |
C04.557.375.460.465 C04.557.450.692.500 C15.604.515.562.465 C20.683.515.710.465
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lymphangioleiomyomatosis".
Below are MeSH descriptors whose meaning is more specific than "Lymphangioleiomyomatosis".
This graph shows the total number of publications written about "Lymphangioleiomyomatosis" by people in this website by year, and whether "Lymphangioleiomyomatosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphangioleiomyomatosis" by people in Profiles.
-
Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion. J Bras Pneumol. 2023; 49(2):e20220356.
-
The lung microbiome in end-stage Lymphangioleiomyomatosis. Respir Res. 2021 Oct 26; 22(1):277.
-
Tuberous Sclerosis: Current Update. Radiographics. 2021 Nov-Dec; 41(7):1992-2010.
-
How we approach the diagnosis and management of complex lymphatic anomalies. Pediatr Blood Cancer. 2022 08; 69 Suppl 3:e28985.
-
Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. Eur Respir J. 2020 05; 55(5).
-
Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells. Chest. 2019 12; 156(6):1137-1148.
-
Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis. Orphanet J Rare Dis. 2019 03 29; 14(1):72.
-
Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Chest. 2018 11; 154(5):1070-1082.
-
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res. 2017 03 15; 77(6):1492-1502.
-
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest. 2017 06; 151(6):1302-1310.